We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Dermatology

Unveiling Dupilumab-Associated Ocular Surface Disease in Atopic Dermatitis: Insights from a Large Prospective BioDay Cohort

MedXY Editorial Team•Sep 12, 2026•Dermatology
atopic dermatitisdupilumabConjunctival Goblet CellsOcular Surface Disease

Highlight

This large prospective study from the BioDay registry provides robust evidence that ocular surface disease (OSD) is highly prevalent in moderate-to-severe atopic dermatitis (AD) patients even before dupilumab treatment. A significant subset (30.7%) developed dupilumab-associated ocular surface disease (DAOSD) during 28 weeks of therapy, despite increased use of ophthalmic medications. Notably, while conjunctival goblet cell (GC) numbers remained stable, dupilumab was associated with decreased mucin 5AC (MUC5AC) production, a critical component for ocular surface health.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Efficacy of Dupilumab in Reducing COPD Exacerbations, Emergency Department Visits, and Corticosteroid Use: Insights from a Pooled Phase 3 AnalysisDupilumab significantly reduces emergency visits, hospital admissions, and systemic corticosteroid use in COPD patients with type 2 inflammation, offering a promising therapeutic option to mitigate exacerbation-associated morbidity.Sep 12, 2026Equivalence of Online and In-Person Care in Managing Atopic Dermatitis: Insights from a Large Randomized TrialA randomized clinical trial shows online team-based care is as effective as conventional in-person treatment for atopic dermatitis, offering an accessible alternative for chronic disease management.Aug 27, 2026Comparative Efficacy of Mepolizumab and Dupilumab in Eosinophilic COPD: Insights from a Matching-Adjusted Indirect Treatment ComparisonA recent MAIC study comparing mepolizumab and dupilumab in eosinophilic COPD patients found no significant difference between the treatments in reducing exacerbations or improving quality of life.Aug 23, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Early Respiratory Infection Burden and Atopic Dermatitis in Childhood: Insights from Prospective Birth Cohorts
Emerging evidence from prospective birth cohorts reveals a dose-dependent association between early respiratory infections and the risk of childhood atopic dermatitis, independent of genetic predisposition and antibiotic exposure.
Aug 20, 2026
Early Prediction of Dupilumab Efficacy in Facial Atopic Dermatitis via Reflectance Confocal Microscopy and Deep LearningReflectance confocal microscopy features at week 4 post-dupilumab treatment, combined with deep learning analysis, enable non-invasive prediction of therapeutic response in facial atopic dermatitis patients.Aug 12, 2026
Optimizing Long-Term Management in Moderate-to-Severe Atopic Dermatitis: Real-World Evidence on 24-Week Abrocitinib Tapering StrategiesThis article reviews a retrospective study evaluating the feasibility and outcomes of a 24-week abrocitinib tapering regimen in moderate-to-severe atopic dermatitis, comparing dose reduction versus interval extension approaches and their imJul 12, 2026